ARGX ArGEN-X SE

argenx Management to Present at Upcoming Virtual Investor Conferences

argenx Management to Present at Upcoming Virtual Investor Conferences



September 2, 2020



Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:

  • Baird Global Healthcare Conference. Fireside chat on Wednesday, September 9, 2020 at 12:15 p.m. ET.
  • Morgan Stanley Global Healthcare Conference. Fireside chat on Monday, September 14, 2020 at 1:30 p.m. ET.
  • BofA Global Healthcare Conference. Fireside chat on Thursday, September 17, 2020 at 10:50 a.m. BST.
  • Stifel Immunology & Inflammation Summit. Panel on Thursday, October 1, 2020 at 11:00 a.m. ET.

Additional information regarding these events will be available on the Company’s website at .

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States and Japan. For more information, visit and follow us on LinkedIn at .

For further information, please contact:

Beth DelGiacco, Vice President, Investor Relations (US)



Joke Comijn, Director Corporate Communications & Investor Relations (EU)

+32 (0)477 77 29 44

+32 (0)9 310 34 19

EN
02/09/2020

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Jacob Mekhael ... (+6)
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
BFIT BASIC-FIT NV
PNL POSTNL NV ... (+8)

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

BFIT BASIC-FIT NV
PNL POSTNL NV
QFG QUEST FOR GROWTH
ARGX ARGEN-X SE
UMI UMICORE
JDEP JDE PEET'S NV
BTLS BIOTALYS NV
ONWD ONWARD MEDICAL NV
1h / 47m 1h / 47m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FDA FAERS reporting flags Vyvgart Hytrulo in routine update

Yesterday during trading hours, the FDA flagged worsening of CIDP with Vyvgart Hytrulo as a new safety signal via a routine update to the FDA adverse event reporting system (FAERS), which sent the argenx' stock down approx. 8%. While CIDP worsening was also reported in patients switching between treatments from IVig to SCig in the PATH study, physicians navigate treatment switches carefully, and based on argenx' own post-marketing surveillance,

1h / 59m 1h / 59m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FIRST LOOK: ARGX-119 Ph1b shows POC in CMS, Ph3 in preparation

argenx announced its plan to advance the clinical development of ARGX-119 (muscle-specific kinase [MuSK] agonist antibody) to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the phase 1b study, which showed consistent improvements through the 12-week study across multiple efficacy scores. This marks the 3rd candidate to advance to phase 3 from argenx' internal pipeline, which in our view supports the company's future growt...

06/30/25 June 30, 2025 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Thomas Couvreur
LEAS LEASINVEST REAL ESTATE SCA
RET RETAIL ESTATES NV
AGFB AGFA-GEVAERT NV
ARGX ARGEN-X SE
FUR FUGRO NV
06/30/25 June 30, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthe...

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of p...

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch